Abstract: Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.

Abstract: The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Abstract: The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Abstract: Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.

Abstract: Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.

Abstract: The invention relates to a method of generating junctional variability in the nucleotide sequence of a polynucleotide of interest present in an intrachromosomal substrate/context in a eukaryotic cell which is competent for canonical Non Homologous End Joining pathway (NHEJ) repair, involving the generation of double-strand break (DSB) in the DNA sequence of said polynucleotide, and involving the use of polymerase Terminal Deoxynucleotidyl Transferase (TdT) in conditions enabling said TdT to add Non-templated nucleotides (N nucleotides) before ligation through the canonical Non Homologous End Joining pathway (NHEJ) thereby allowing a mutagenic repair to take place at the DSB site.

Abstract: The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Abstract: The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against a glial fibrillary acidic protein and uses thereof for preparing therapeutic or diagnostic agents.

Abstract: Use of camelid single-domain antibodies for detecting an oligomeric form of the amyloid ? peptide 42 and their therapeutic and diagnostic applications.

Abstract: The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human.

Abstract: Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.

Abstract: A process for screening for a ligand molecule that possesses an agonist biological activity on the NEP binding site for an SMR1 peptide, such as the QHNPR (SEQ ID NO: 2) pentapeptide. The method comprises preparing a cell culture or preparing an organ specimen or a tissue sample containing NEP binding sites for an SMR1 peptide, incubating the cell culture, organ specimen or tissue sample of at concentrations allowing measurement of NEP enzymatic activity under initial velocity conditions in the presence of a candidate ligand molecule, a half-saturating concentration of an SMR1 peptide, and a NEP substrate during a time sufficient for the hydrolysis activity of the NEP substrate to take place under initial velocity conditions; and quantifying the activity of the NEP present in the biological material of by measuring the levels of NEP substrate hydrolysis, respectively in the presence or in the absence of the ligand molecule and in the presence or in the absence of the SMR1 peptide.

Abstract: The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions.

Abstract: This invention relates to the use of an agent that modulates the interaction between a SMR1 peptide and a metal-lopeptidase for the preparation of a medicament for preventing or treating a Central Nervous System disorder giving rise to a mental disorder.

Abstract: The invention relates to the field of psychopharmacology. More particularly, the invention relates to the treatment of mental disorders, such as impaired interpersonal and behavioral disorders, including sexual disorders such as M.E.D. and H.S.D.D. The invention provides new therapeutic compositions and methods for treating mental disorders, including M.E.D. and H.S.D.D. The compositions and methods according to the invention provide improved awareness and alertness to environment, improved adaptation to environment and ability to sustain attention, and increased interest in environment and capacity for arousal, without increased aggressiveness.

Abstract: The invention relates to the therapeutic use of a SMR1-peptide or a pharmaceutically active amount of said SMR1-peptide, for the preparation of a therapeutic composition for preventing or treating diseases wherein a modulation of the activity of a membrane metallopeptidase, notably a membrane-zinc metallopeptidase, is sought, in a mammal, specifically in a human.

Abstract: A method for treating or reducing the severity of a disease or disorder mediated by a membrane metallopeptidase by administering to a mammal a SMR1-peptide or a pharmaceutically active amount of a SMR1-peptide.

Abstract: The invention relates to peptides having the formula (I): X-His-Asn-Pro-Y wherein X is a rest Gln or pyro-Glu. Y is a group OH or a rest of basic aminoacid.

Abstract: The present invention relates to peptides and polypeptide derived from the submaxillary gland of the rat. In particular, the present invention discloses a purified peptide of formuls: X-His-Asn-Pro-Y in which X represents a Gln or Pro-Glu residue and Y represents an OH group or residue of a basic amino acid. The present invention also relates to corresponding polyclonal and monoclonal antibodies as well as corresponding hybridomas. The products of the present invention are useful for therapeutic, diagnosis and detection purposes.

Abstract: The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions.